| Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events M Guerrini, D Beccati, Z Shriver, A Naggi, K Viswanathan, A Bisio, I Capila, ... Nature biotechnology 26 (6), 669-675, 2008 | 706 | 2008 |
| Outbreak of adverse reactions associated with contaminated heparin DB Blossom, AJ Kallen, PR Patel, A Elward, L Robinson, G Gao, ... New England Journal of Medicine 359 (25), 2674-2684, 2008 | 322 | 2008 |
| Anti-dengue virus antibodies and uses thereof R Sasisekharan, LN Robinson, K Tharakaraman US Patent App. 15/833,110, 2018 | 281 | 2018 |
| Structure-guided design of an anti-dengue antibody directed to a non-immunodominant epitope LN Robinson, K Tharakaraman, KJ Rowley, VV Costa, KR Chan, ... Cell 162 (3), 493-504, 2015 | 139 | 2015 |
| Redesign of a cross-reactive antibody to dengue virus with broad-spectrum activity and increased in vivo potency K Tharakaraman, LN Robinson, A Hatas, YL Chen, L Siyue, S Raguram, ... Proceedings of the National Academy of Sciences 110 (17), E1555-E1564, 2013 | 91 | 2013 |
| Recognition of heparan sulfate by clinical strains of dengue virus serotype 1 using recombinant subviral particles C Artpradit, LN Robinson, BK Gavrilov, TT Rurak, M Ruchirawat, ... Virus research 176 (1-2), 69-77, 2013 | 51 | 2013 |
| Harnessing glycomics technologies: integrating structure with function for glycan characterization LN Robinson, C Artpradit, R Raman, ZH Shriver, M Ruchirawat, ... Electrophoresis 33 (5), 797-814, 2012 | 43 | 2012 |
| Preclinical evaluation of VIS513, a therapeutic antibody against dengue virus, in non-human primates EZ Ong, Y Budigi, HC Tan, LN Robinson, KJ Rowley, A Winnett, S Hobbie, ... Antiviral research 144, 44-47, 2017 | 23 | 2017 |
| Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein Y Budigi, EZ Ong, LN Robinson, LC Ong, KJ Rowley, A Winnett, HC Tan, ... PLoS neglected tropical diseases 12 (2), e0006209, 2018 | 21 | 2018 |
| Antibody molecules to dengue virus and uses thereof L Robinson, Z Shriver, J Myette, G Babcock, K Viswanathan US Patent 9,212,217, 2015 | 14 | 2015 |
| Anti-dengue virus antibodies and uses thereof R Sasisekharan, LN Robinson, K Tharakaraman US Patent 9,499,607, 2016 | 13 | 2016 |
| Structural prediction of antibody‐APRIL complexes by computational docking constrained by antigen saturation mutagenesis library data AM Wollacott, LN Robinson, B Ramakrishnan, H Tissire, K Viswanathan, ... Journal of Molecular Recognition 32 (7), e2778, 2019 | 10 | 2019 |
| Antibody molecules to zika virus and uses thereof AM Wollacott, L Robinson, G Babcock, ZH Shriver US Patent App. 15/488,153, 2017 | 9 | 2017 |
| Antibody molecules to dengue virus and uses thereof L Robinson, Z Shriver, J Myette, G Babcock, K Viswanathan US Patent 9,365,639, 2016 | 8 | 2016 |
| Anti-dengue virus antibodies and uses thereof R Sasisekharan, LN Robinson, K Tharakaraman US Patent 9,880,167, 2018 | 7 | 2018 |
| Vibratory finishing apparatus, fixtures and method T Yebing, CC Wong, ONG Wallace, CY Liew, L Robinson US Patent 10,166,651, 2019 | 5 | 2019 |
| Antibody molecules to dengue virus and uses thereof L Robinson, Z Shriver, JR Myette, G Babcock, K Viswanathan US Patent 10,155,806, 2018 | 5 | 2018 |
| Anti-dengue virus antibodies and uses thereof R Sasisekharan, LN Robinson, K Tharakaraman US Patent App. 16/790,289, 2020 | 3 | 2020 |
| Antibody molecules to dengue virus and uses thereof L Robinson, Z Shriver, JR Myette, G Babcock, K Viswanathan US Patent 11,059,883, 2021 | 2 | 2021 |
| Multi-omic single cell sequencing: Overview and opportunities for kidney disease therapeutic development S Pregizer, T Vreven, M Mathur, LN Robinson Frontiers in Molecular Biosciences 10, 1176856, 2023 | 1 | 2023 |
